Brodde O E, Gross G
Naunyn Schmiedebergs Arch Pharmacol. 1980 Apr;311(3):249-54. doi: 10.1007/BF00569404.
The potent dopamine receptor antagonist [3H]-spiroperidol was used to label binding sites in a membrane fraction derived from rabbit mesenteric artery which had characteristics expected for dopamine receptors. The binding was of high affinity with an equilibrium dissociation constant (KD) of 13.1 nM; it was saturable with 110 fmol of [3H]-spiroperidol bound/mg protein at maximal occupancy of the sites. Binding at 37 degrees C was rapid and readily reversible with rate constants of 0.0154nM-1 min-1 and 0.114min-1 for forward and reverse reaction, respectively. Dopamine receptor antagonists were about 100--200 times more potent than alpha-adrenolytic drugs in competing for the [3H]-spiroperidol binding sites and dopamine was much more potent than (-)-noradrenaline, (-)-isoprenaline, clonidine or serotonin. It is concluded that in a membrane fraction of the rabbit mesenteric artery there exist binding sites for [eH]-spiroperidol indistinguishable from dopamine receptors. Thus the present results support the view that in vascular smooth muscle there exist specific dopamine receptors.
强效多巴胺受体拮抗剂[3H]-螺哌啶醇用于标记从兔肠系膜动脉获得的膜组分中的结合位点,这些位点具有多巴胺受体预期的特征。该结合具有高亲和力,平衡解离常数(KD)为13.1 nM;在位点最大占据时,每毫克蛋白质结合110 fmol的[3H]-螺哌啶醇时可饱和。37℃下的结合迅速且易于逆转,正向和反向反应的速率常数分别为0.0154 nM-1 min-1和0.114 min-1。多巴胺受体拮抗剂在竞争[3H]-螺哌啶醇结合位点方面比α-肾上腺素能阻断药强约100 - 200倍,且多巴胺比(-)-去甲肾上腺素、(-)-异丙肾上腺素、可乐定或5-羟色胺强得多。得出结论,在兔肠系膜动脉的膜组分中存在与多巴胺受体无法区分的[3H]-螺哌啶醇结合位点。因此,目前的结果支持血管平滑肌中存在特异性多巴胺受体这一观点。